Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders

By Hoppensteadt Debra A   Kaiser Brigitte   Fareed Jawed  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 11, 2001-11 ,pp. : 1925-1935

Informa Healthcare

Access to resources Recommend Favorite

Immediate Effects of Fluvastain on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes

By Atalar Enver   Coskun Secuk   Haznedaroglu Ibrahim   Yücel Neslihan   Ozer Necla   Sivri Bulent   Aksoyek Serdar   Ovunc Kenan   Ozmen Ferhan  

Cardiovascular Drugs and Therapy, Vol. 19, Iss. 3, 2005-05 ,pp. : 177-181

Springer Publishing Company

Access to resources Recommend Favorite

The multivalent activity of the tissue factor–thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention

By Mitroulis Ioannis   Kambas Konstantinos   Anyfanti Panagiota   Doumas Michael   Ritis Konstantinos  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 75-89

Informa Healthcare

Access to resources Recommend Favorite

Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan

By  

Current Bioactive Compounds, Vol. 11, Iss. 4, 2015-12 ,pp. : 210-214

Bentham Science Publishers

Access to resources Recommend Favorite

Tissue factor – a therapeutic target for thrombotic disorders

By Houston Donald S  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 2, 2002-04 ,pp. : 159-174

Informa Healthcare

Access to resources Recommend Favorite